Fenestrated Amplatzer septal occluder implantation was safely accomplished with 0% complications in 15 high-risk ASD patients, improving NYHA class and decreasing pulmonary artery pressure.
Does a fenestrated septal occluder safely improve symptoms and hemodynamics in elderly ASD patients with pulmonary hypertension and/or right heart failure?
Fenestrated ASD occlusion is a safe and feasible approach for high-risk elderly patients with pulmonary hypertension or right heart failure, preventing post-procedural heart failure deterioration.
Atrial septal defect (ASD) occlusion in adult patients with advanced age and left or right heart diastolic or systolic heart failure and in patients with pulmonary arterial hypertension bears a considerable risk of deterioration of heart failure. Therefore, we conducted this feasibility trial in 15 ASD patients with pulmonary hypertension and/or right heart failure using a fenestrated Amplatzer septal occluder (AGA Medical Corporation, Golden Valley, MN), allowing an overflow of blood in both directions in case of univentricular diastolic or systolic heart failure. In all patients, the device could be implanted without complications. All symptomatic patients showed an improvement in the New York Heart Association (NYHA) class, and no right or left heart decompensation occurred. On echocardiography, right ventricular end diastolic dimension (RVEDD) and pulmonary artery pressure (PAP) decreased significantly, whereas left ventricular end diastolic dimension (LVEDD) increased. Our series of 15 patients with fenestrated ASD occlusion shows that high-risk ASD occlusion can safely be accomplished with excellent clinical results and without complications by a fenestrated occluder.
Bruch et al. (Thu,) conducted a other in Atrial septal defect with pulmonary hypertension and/or right heart failure (n=15). Fenestrated Amplatzer septal occluder was evaluated on Complications during device implantation. Fenestrated Amplatzer septal occluder implantation was safely accomplished with 0% complications in 15 high-risk ASD patients, improving NYHA class and decreasing pulmonary artery pressure.